Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22213099 | 0.89 | LPAR3 (0.47) | LPAR3LPAR2LPAR1ALDH1A1KMT2A | |
| SCHEMBL16300835 | 0.86 | LPAR3 (0.39) | LPAR3LPAR2LPAR1ALDH1A1KDM4E | |
| SCHEMBL13400473 | 0.85 | LPAR3 (0.53) | LPAR3LPAR2LPAR1 | |
| SCHEMBL14407788 | 0.82 | ALDH1A1 (0.41) | LPAR3LPAR2LPAR1ALDH1A1KMT2A | |
| SCHEMBL3428966 | 0.82 | ALDH1A1 (0.41) | LPAR3LPAR2LPAR1ALDH1A1KMT2A | |
| SCHEMBL3428964 | 0.82 | LPAR3 (0.35) | LPAR3LPAR2LPAR1 | |
| SCHEMBL7521230 | 0.82 | MAPT (0.45) | LPAR3LPAR2LPAR1ALDH1A1KMT2A | |
| SCHEMBL10175171 | 0.80 | DAO (0.38) | LPAR3LPAR2LPAR1ALDH1A1KDM4E | |
| SCHEMBL3434049 | 0.79 | LPAR3 (0.37) | LPAR3LPAR2LPAR1 | |
| SCHEMBL3434052 | 0.79 | LMNA (0.40) | LPAR3LPAR2LPAR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481571-B2 | Anti-coronavirus compounds | ACADEMIA SINICA (TW) | 2013-07-09 | — | — | US | disclosed |
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | INOTEK PHARMACEUTICALS CORPORATION | 2010-01-07 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | LPAR3 2453/4885LPAR2 2408/4885LPAR1 2868/4885 |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | LPAR3 2453/4885LPAR2 2408/4885LPAR1 2868/4885 |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | TNNI3, IDH2, GLS | LPAR3 2453/4885LPAR2 2408/4885LPAR1 2868/4885 |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | LPAR3 2453/4885LPAR2 2408/4885LPAR1 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.